<DOC>
	<DOCNO>NCT02990819</DOCNO>
	<brief_summary>This Phase II trial determine ability reduce intensity condition regimen allow successful engraftment alpha/beta T CD19+ deplete peripheral stem cell graft unrelated partially match related donor . There two conditioning regimen depend upon patient diagnosis age .</brief_summary>
	<brief_title>Alpha/Beta T CD19+ Depleted Peripheral Stem Cells Patients With Primary Immunodeficiencies</brief_title>
	<detailed_description>This Phase II trial determine ability reduce intensity condition regimen allow successful engraftment alpha/beta T CD19+ deplete peripheral stem cell graft unrelated partially match related donor . There two conditioning regimen depend upon patient diagnosis age . The study include patient 0-22 year PID , include immune dysregulation syndrome hematopoietic stem cell transplant indicate . Treatment : Either condition regimen ( list ) follow alpha/beta T CD19+ deplete donor peripheral stem cell 1 . Reduced intensity condition busulfan x 8 dos , fludarabine 40 mg/m2 x 4 , thiotepa 5 mg/kg x 2 , ATG 3 mg/kg x 3 . OR 2 . Myeloablative regimen busulfan x 16 dos Daily four day , fludarabine 30 mg/m2 x 5 , thiotepa 5 mg/kg x 2 , ATG 3 mg/kg x 2 . 3 . Infusion alpha/beta T CD19+ deplete donor peripheral stem cell . 4 . Follow , include evaluation chimerism immune reconstitution .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<criteria>1 . Ages 022 year time enrollment 2 . Diseases : Immunodeficiencies allogeneic hematopoietic stem cell transplant indicate , include severe combine immunodeficiency , IPEX syndrome , Xlinked lymphoproliferative disease , chronic granulomatous disease , WAS , hyperIgM , lifethreatening immunodeficiency . Immune dysregulation syndrome , include refractory recurrent hemophagocytic lymphohistiocytosis , HLH genetic mutation , refractory multisystemic Langerhans cell histiocytosis , MAS refractory standard therapy . 3 . Clinical status Lansky Karnofsky performance &gt; 60 Organ Function : 1 . Serum creatinine &lt; 1.5 x upper limit normal age Hepatic : ALT &lt; 250 ; AST &lt; 350 2 . Cardiac shorten fraction &gt; 27 % 3 . Bilirubin &lt; 2.5x normal ( unless elevation due Gilberts disease ) . 4 . No active untreated infection 4 . Signed informed consent 5 . No HLA match related donor available . 6 . Females childbearing potential must negative pregnancy test . Uncontrolled bacterial , viral fungal infection HLA match related unrelated donor able donate mobilize peripheral stem cell . Pregnant Females Matched relate donor available bone marrow donation Donors Selection Criteria : Donor selection comply 21 CFR 1271 Unrelated donor match one antigen mismatch per National Marrow Donor Program ( NMDP ) . Haploidentical parent sibling able undergo mobilization peripheral stem cell collection . Maternal donor prefer paternal donor equally haploidentical . CHOP BMT procedures apply determine donor eligibility , include donor screen test relevant communicable disease agent diseases . Unrelated donor identify National Marrow Donor Program ( NMDP ) fulfill NMDP criterion donation . Unrelated donor willing able undergo mobilization peripheral stem cell apheresis</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>22 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Immunodeficiencies</keyword>
	<keyword>Immune dysregulation syndrome</keyword>
</DOC>